SOLAI Limited vs Viatris Inc — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 1119.8× SOLAI Limited's market cap, and Viatris Inc pays a 2.95% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| SLAI | VTRS | |
|---|---|---|
Market Cap | $16.69M | $18.69B |
Sector | Technology | Health |
52-Week High | $26.74 | $17.86 |
52-Week Low | $2.74 | $9.49 |
Enterprise Value | $16.33M | $30.80B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price change. The stock shows a bullish technical signal, but the company faces severe financial distress with negative gross and net income margins, and a net loss of $33.88 million in 2025. A reverse stock split was executed on July 6, 2026, and the NYSE has commenced delisting proceedings, creating significant uncertainty.
The outlook is highly speculative. The acquisition of a stake in NEURALAND and the launch of Solode Neo represent potential growth avenues, but the delisting risk and persistent losses overshadow any near-term upside. Investors face substantial risk of capital loss.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Trailing returns across standard periods
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →